Comparing the Nucleocapsid Proteins of Human Coronaviruses: Structure, Immunoregulation, Vaccine, and Targeted Drug

• Published in: Frontiers in molecular biosciences Vol. 9; p. 761173
• Main Authors: Zhang, Bo, Tian, Junjie, Zhang, Qintao, Xie, Yan, Wang, Kejia, Qiu, Shuyi, Lu, Keyu, Liu, Yang
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 29.04.2022
• Subjects: coronaviruses; immunoregulation; Molecular Biosciences; nucleocapsid protein; structure; targeted drug; vaccine; immunoregulation; nucleocapsid protein; vaccine; coronaviruses; targeted drug; structure
• ISSN: 2296-889X; 2296-889X
• DOI: 10.3389/fmolb.2022.761173

The seven pathogenic human coronaviruses (HCoVs) include HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1, which usually cause mild upper respiratory tract diseases, and SARS-CoV, MERS-CoV, and SARS-CoV-2, which cause a severe acute respiratory syndrome. The nucleocapsid (N) protein, as the dominant structural protein from coronaviruses that bind to the genomic RNA, participates in various vital activities after virus invasion and will probably become a promising target of antiviral drug design. Therefore, a comprehensive literature review of human coronavirus' pathogenic mechanism and therapeutic strategies is necessary for the control of the pandemic. Here, we give a systematic summary of the structures, immunoregulation, and potential vaccines and targeted drugs of the HCoVs N protein. First, we provide a general introduction to the fundamental structures and molecular function of N protein. Next, we outline the N protein mediated immune regulation and pathogenesis mechanism. Finally, we comprehensively summarize the development of potential N protein-targeted drugs and candidate vaccines to treat coronavirus disease 2019 (COVID-19). We believe this review provides insight into the virulence and transmission of SARS-CoV-2 as well as support for further study on epidemic control of COVID-19.